The FY2025 (Dec) proxy of Zymeworks names 19 peer companies for pay. Among Zymeworks and these peers, CEO pay was 4th highest of 9 and total shareholder return was 2nd highest of 9.
4th highest of 9in Zymeworks and its pay peers, FY2025 (Dec) by CEO pay:
$4.2M$27.8M
2nd highest of 9in Zymeworks and its pay peers, FY2025 (Dec) by total shareholder return:
$20$414
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| Arcus Biosciences | ||
| Immunome | ||
| Anaptysbio | ||
| Cullinan Therapeutics | ||
| Kura Oncology | ||
| Relay Therapeutics | ||
| Regenxbio | ||
| Alector, Inc. | Not disclosed | Not disclosed |
| Bicycle Therapeutics | Not disclosed | Not disclosed |
| C4 Therapeutics | Not disclosed | Not disclosed |
| Erasca | Not disclosed | Not disclosed |
| IGM Biosciences, Inc. | Not disclosed | Not disclosed |
| Iteos Therapeutics | Not disclosed | Not disclosed |
| MacroGenics, Inc. | Not disclosed | Not disclosed |
| Replimune Group, Inc. | Not disclosed | Not disclosed |
| Sutro Biopharma, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.